Early evidence from the Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy (ARTS-DN) trial demonstrated Finerenone’s ability to significantly reduce proteinuria in patients with diabetic nephropathy who were already on ACEi’s or ARBs, with reductions in the urinary albumin–creatinine ratio (UACR) at higher doses [21]. This evidence concerns the gene ALB and diabetic kidney disease.